Boehringer’s reach into the most cutting-edge science continues through its new deal with Enara to access dark antigen targets for cancer immunotherapies.  Boehringer Ingelheim GmbH teamed up with...

European investment firm LSP has launched a new dementia-focused fund to fill what it believes is a gap in support for development-stage companies evaluating treatments for neurodegenerative diseases. The firm has named Philip Scheltens, who...

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...

Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company named Warburg Pincus, OrbiMed, Lake Bleu Capital and an...

Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...

Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.”  SV’s Houman Ashrafian...

Kate Bingham will step down, as planned, as chair of the U.K. Vaccine Taskforce in the coming weeks. Bingham joined the COVID-focused task force in May shortly after its launch with a commitment to...

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...

This is the fifth and final article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient...

This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...